Search and analyze individual stocks with comprehensive metrics
BALAXI PHARMACEUTICALS LIMITED
Fundamental Score
BALAXI PHARMACEUTICALS LIMITED Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of BALAXI across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Operating Margins (16.50%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 13.15 vs Industry: 33.97)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Consistent Growth Track Record (45.01% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (30.15% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (32.75% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.23)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (7.20x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (65.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
5 factors identified
Profit Decline Concern (-95.52%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Negative Free Cash Flow (₹-57.60 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 8.89%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for BALAXI PHARMACEUTICALS LIMITED
About BALAXI
Company Details
Market Information
Performance
BALAXI Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of BALAXI?
BALAXI is currently trading at ₹43.70 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of BALAXI shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of BALAXI and what does it mean?
BALAXI has a P/E ratio of 13.15x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹13 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is BALAXI performing according to Bull Run's analysis?
BALAXI has a Bull Run fundamental score of 56.4/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 11.61%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does BALAXI belong to?
BALAXI operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting BALAXI PHARMACEUTICALS LIMITED. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for BALAXI?
BALAXI has an ROE of 11.61%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently BALAXI PHARMACEUTICALS LIMITED generates profits from shareholders' equity. An ROE of 12% means the company generates ₹12 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is BALAXI's debt-to-equity ratio and what does it indicate?
BALAXI has a debt-to-equity ratio of 0.23, which indicates conservative financing with low financial risk. This means the company has ₹23 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is BALAXI's dividend yield and is it a good dividend stock?
BALAXI offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has BALAXI grown over the past 5 years?
BALAXI has achieved 5-year growth rates of: Sales Growth 45.01%, Profit Growth 32.75%, and EPS Growth 30.15%. This consistent double-digit growth indicates a strong business model and competitive positioning. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in BALAXI and why does it matter?
Promoters hold 65.99% of BALAXI shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does BALAXI compare with its industry peers?
BALAXI trades at P/E 13.15x vs industry average 33.97x, with ROE of 11.61% and ROCE of 12.95%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether BALAXI is outperforming its competitive set in profitability, growth, and valuation metrics.
What is BALAXI's market capitalization and what category does it fall into?
BALAXI has a market capitalization of ₹248 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for BALAXI?
Key ratios for BALAXI: ROE 11.61% (Good), ROCE 12.95%, P/E 13.15x, Debt-to-Equity 0.23, Interest Coverage 7.20x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is BALAXI stock and what is its beta?
BALAXI has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for BALAXI?
BALAXI has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹43.70, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in BALAXI?
Key risks for BALAXI include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.23), and operational challenges. The stock has a Fundamental Score of 56.4/100, indicating moderate risk requiring careful monitoring. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is BALAXI's operating profit margin and how has it trended?
BALAXI has a 5-year average Operating Profit Margin (OPM) of 16.50%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is BALAXI's quarterly performance in terms of sales and profit growth?
BALAXI's recent quarterly performance shows YoY Sales Growth of 7.80% and YoY Profit Growth of -95.52%. Growth rates indicate the current business trajectory and market demand. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in BALAXI?
BALAXI has FII holding of 8.87% and DII holding of 0.02%, totaling 8.89% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.